跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ENSPRYNG - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ENSPRYNG
Authorized
STANDARD
ENSPRYNG
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f486007e0a8fccb9
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
f486007e0a8fccb9
Drug Approval Canada Name
ENSPRYNG
Product Name
ENSPRYNG
Status
Marketed
Status Date
2020-08-26
Original Market Date
2020-08-26
Din
02499681
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
92:20.00
Atc Original
L04AC19 SATRALIZUMAB
Atc Name
l 04 ac 19
Aig Number
0162294001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
SATRALIZUMAB
120 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f486007e0a8fccb9
Type
Standard
Back to Health Canada Approvals